Biological treatments for systemic lupus erythematosus

Scandinavian Journal of Rheumatology

Volumn 31, Issue 4, 2002, Pages 187-191

  Isenberg, David ^a   Leckie, M J ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Cytokines; SLE

Indexed keywords

ANTIGEN; AUTOANTIBODY; AZATHIOPRINE; B7 ANTIGEN; CD20 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IG; GAMMA INTERFERON; HORMONE; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LPJ 394; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OKT 4; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BIOLOGICAL THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0036353226     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097402320318350     Document Type: Review

References (38)

1. Systemic lupus erythematosis
2. Defective antigen-presenting cell function in patients with systemic lupus erythematosis
3. Cytokine mediated down-regulation of B cell activity in SLE: Effects of interleukin-2 and transforming growth factor-beta
4. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells
5. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
6. Cytokines and systemic lupus erythematosus
7. Serum IL-6. TNF alpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosis
8. Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis
9. Elevated levels of interleukin-6 in cerebro-spinal fluid from patients with systemic lupus erythematosis and central nervous system involvement
10. Urinary IL-6: A marker for mesangial proliferative glomerulonephritis
11. The role of IFN-gamma in systemic lupus erythematosus: A challenge to the Th1/Th2 paradigm in autoimmunity
12. IFN-gamma transgenic mice: Clues to the pathogenesis of systemic lupus erythematosus?
13. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines
14. Spontaneous production of interluekin-10 by B lymphocytes and monocytes in systemic lupus erythematosis
15. Serum interleukin-10 titres in systemic lupus eryhtematosus reflect diease activity
16. Increased CCR4 expression in active systemic lupus erythematosus
17. Role of interleukin 10 in B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
18. Interleukin-10 differentially regulates B7-1(CD80) and B7-2(CD86) expression on human peripheral blood dendritic cells
19. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients
20. Impaired production of IL-12 in systemic lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE
21. Impaired production of IL-12 in systemic lupus erythematosus. I: Excessive production of IL-10 suppresses production of IL-12 by monocytes
22. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus
23. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus
24. Interleukin 10: A new therapeutic target in systemic lupus erythematosus?
25. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline
26. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice
27. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice
28. Anticytokine gene therapy of autoimmune diseases
29. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4
30. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis
31. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients iwth systemic lupus erythematosus
32. Treatment of murine lupus with CTLA4 Ig
33. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis
34. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 constimulation pathways
35. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus
36. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
37. Treatment of systemic lupus erythematosus with LJP 394
38. An open study of B lymphocyte depletion in systemic lupus erythematosus